Fore Biotherapeutics
Matthew is a Partner at SROne in its London office. Matthew has 20 years of investment and finance experience, having been part of SROne since 2011 and previously at Greenhill & Co. In addition to Fore, he currently serves on the boards of PsiOxus Therapeutics, Pulmocide, Decibel Therapeutics, AtoxBio and Rockend. His academic background is in molecular biology from the University of Oxford.
This person is not in the org chart
This person is not in any offices
Fore Biotherapeutics
Fore Biotherapeutics is a precision oncology company rooted in science and innovation, developing cancer therapies guided by functional genomics.